Cara Therapeutics (NASDAQ: CARA)
Cara Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Cara Therapeutics Company Info
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
News & Analysis
Is Cara Therapeutics Stock a Buy After Its First FDA Drug Approval
There's good news at long last for the beaten-down biotech stock.
Why Cara Therapeutics Shot Higher Today
The biotech gets an important nod from a top regulator.
Is Cara Therapeutics a Buy for Summer 2021?
The future of this troubled clinical-stage biotech rests on a single drug candidate -- but one it hopes will treat an extremely common condition.
Is Cara Therapeutics a Buy?
Maybe, if you're itching to speculate.
Why Cara Therapeutics Stock Is Crashing Today
The company reported disappointing results from a phase 2 study.
Why Cara Therapeutics Stock Is Soaring Higher Today
The biotech stock is being added to an important small-cap index.
Better Buy: GW Pharmaceuticals vs. Cara Therapeutics
Both of these biotechs could have big catalysts on the way.
3 Pot Stocks Worth a Second Look
These companies are all surprising a few doubters lately.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.